Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jiangsu Recbio Technology CoFRA:G93 24 OCF Yield % is -17.65 as of Aug. 25, 2026. GuruFocus rates FRA:G93 with a GF Score™ of 24/100. The stock has 6 warning signs investors should review. Among 1,410 Biotechnology companies, Jiangsu Recbio Technology Co ranks worse than 65.74% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Jiangsu Recbio Technology Co OCF Yield % Explanation
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Jiangsu Recbio Technology Co OCF Yield % Related Terms
Jiangsu Recbio Technology Co OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:G93 vs VRTX, REGN, RVMD: OCF Yield % Comparison
For the Biotechnology subindustry, Jiangsu Recbio Technology Co's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Recbio Technology Co OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jiangsu Recbio Technology Co's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Jiangsu Recbio Technology Co's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Recbio Technology Co (FRA:G93) has a OCF Yield % of -17.65 as of Aug. 25, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Jiangsu Recbio Technology Co and its competitors. According to the industry distribution chart, Jiangsu Recbio Technology Co ranks #927 out of 1410 companies in the Biotechnology industry, placing it in the top 65.7%.
Is Jiangsu Recbio Technology Co's OCF Yield % too high?
Jiangsu Recbio Technology Co's current OCF Yield % is -17.65. Based on the distribution chart, Jiangsu Recbio Technology Co ranks #927 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Jiangsu Recbio Technology Co has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Recbio Technology Co's OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jiangsu Recbio Technology Co ranks #927 out of 1410 companies for OCF Yield %. This places Jiangsu Recbio Technology Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Jiangsu Recbio Technology Co and its competitors. Jiangsu Recbio Technology Co's current OCF Yield % is -17.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Recbio Technology Co stock overvalued right now?
Jiangsu Recbio Technology Co (FRA:G93) has a current OCF Yield % of -17.65. The current OCF Yield % is -17.65. Jiangsu Recbio Technology Co's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Jiangsu Recbio Technology Co (FRA:G93), the current OCF Yield % is -17.65 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jiangsu Recbio Technology Co Ltd is a vaccine company focused on the research, development, and commercialization of vaccines, with a high-value vaccine portfolio driven by in-house technologies. It has built three vaccine technology platforms: novel adjuvants, protein engineering, and immune evaluation. The company's portfolio currently consists of various vaccines, covering diseases such as cervical cancer, herpes zoster, and respiratory syncytial virus. It has two core strategic products, namely REC610, a novel adjuvanted recombinant shingles vaccine, which is currently in the stage of marketing application in China, and REC603, a recombinant HPV 9-valent vaccine under phase three clinical trial.
24GF Score
Get the complete analysis for FRA:G93
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:G93 has been successfully added to your 
